California Man Blames Xarelto for Subdural Hematoma

Posted on August 17, 2016

A California man has filed a personal injury claim against both the manufacturer and marketer of Xarelto (rivaroxaban): Bayer AG and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals. The man says he began taking the anticoagulant in July of 2013 to reduce the risk of stroke associated with atrial fibrillation. He had been prescribed the medication by his physician. The man continued taking the medication until April 2014, when he suffered life threatening bleeding and a subdural hematoma that caused severe and permanent physical injuries.

A subdural hematoma occurs when blood collects between the covering of the brain (the dura) and the surface of the brain. A subdural hematoma is often caused by a serious head injury and is referred to as an “acute” subdural hematoma. Acute subdural hematomas are one of the most dangerous head injuries one can suffer. The blood fills the brain area very quickly and compresses brain tissue. This can result in brain injury and possibly death.

Xarelto was approved for use by the U.S. Food and Drug Administration (FDA) in 2011 and quickly became one of the nation’;s best selling medications for treating blood clots. Part of Xarelto’s popularity is, no doubt, due to the fact that it doesn’t require a special diet and frequent blood monitoring like its competitor, Warfarin. Both medications can cause excessive bleeding, but the difference is that Warfarin has an antidote while Xarelto does not. This has led to numerous cases of a patients being treated with Xareto bleeding to death.

If you suffered severe bleeding or lost a loved one due to Xarelto use, you may be eligible to file a personal injury claim. To find out more about your legal rights and options, contact the pharmaceutical litigation attorneys at Farah & Farah. We are currently investigating Xarelto stroke related injuries nationwide. Farah & Farah can be reached at (800) 533-3555. Your initial consultation is free of charge.



  • This field is for validation purposes and should be left unchanged.